Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0
|
作者：
Mauro, Michael [1 ]
Hochhaus, Andreas [2 ]
Hughes, Timothy [3 ,4 ]
Rea, Delphine [5 ]
Boquimpani, Carla [6 ]
Minami, Yosuke [7 ]
Apperley, Jane [8 ]
Garcia-Gutierrez, Valentin [9 ]
Kapoor, Shruti [10 ]
Espurz, Noemi [11 ]
Dhamal, Vishal [12 ]
Cortes, Jorge [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Klinikum Jena, Jena, Germany
[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[4] Univ Adelaide, Adelaide, SA, Australia
[5] Hop St Louis, Paris, France
[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[8] Ctr Haematol Imperial Coll London, London, England
[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Georgia Canc Ctr, Augusta, GA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; asciminib; TKI; ASCEMBL; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-398
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [41] Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study
    Minami, Yosuke
    Doki, Noriko
    Matsuoka, Hiroshi
    Yokota, Takafumi
    Tomita, Akihiro
    Takahashi, Naoto
    Kubo, Kohmei
    Goto, Tatsunori
    Kirito, Keita
    Maki, Akio
    Aoki, Makoto
    Dawson, Meryem Ktiouet
    Matsumura, Itaru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) : 305 - 313
  • [42] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without the T315I Mutation
    Levy, Moshe Y.
    Mauro, Michael J.
    Issa, Ghayas C.
    Andorsky, David
    Tomassetti, Sarah
    Broun, E. Randolph
    Maegawa, Rodrigo
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S298 - S298
  • [43] An Observational Study of Survival in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) After 1, 3, and 5 Years of Tyrosine Kinase Inhibitor (TKI) Therapy (SIMPLICITY)
    Michallet, Mauricette
    Cortes, Jorge
    Gambacorti-Passerini, Carlo
    Hehlmann, Rudiger
    Williams, Loretta A.
    Goldberg, Stuart L.
    Davis, Catherine
    De Solda, Francesco
    Sen, Ginny P.
    Gajavelli, Srikanth
    Mauro, Michael J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S229 - S229
  • [44] AIM4CML Trial in Progress: A Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I Mutations
    Levy, Moshe Y.
    Mauro, Michael J.
    Issa, Ghayas C.
    Andorsky, David
    Tomassetti, Sarah
    Maegawa, Rodrigo
    Shrestha, Alok
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S334 - S335
  • [45] Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study
    Gjertsen, Bjorn T.
    Hochhaus, Andreas
    Rosti, Gianantonio
    Watts, Justin M.
    Orti, Guillermo
    le Coutre, Philipp
    Leip, Eric
    Viqueira, Andrea
    Cortes, Jorge E.
    Giles, Frank
    Gambacorti-Passerini, Carlo
    BLOOD, 2019, 134
  • [46] Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION
    Breccia, Massimo
    Mauro, Michael
    Jabbour, Elias
    Saglio, Giuseppe
    Jimenez-Velasco, Antonio
    le Coutre, Philipp
    DeGutis, Irene
    Khan, Wasiulla
    Sy, Oumar
    Swanink, Rene
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S326 - S327
  • [47] Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
    Giles, Francis
    le Coutre, Philipp D.
    Bhalla, Kapil N.
    Ossenkoppele, Gert J.
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil J.
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [48] Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison
    Levy, Moshe Yair
    McGarry, Lisa J.
    Huang, Hui
    Lustgarten, Stephanie
    Nieset, Christopher
    Haluska, Frank G.
    BLOOD, 2014, 124 (21)
  • [49] Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.
    Atallah, Ehab L.
    Sadek, Islam
    Maegawa, Rodrigo O.
    Cao, Xiting
    Latremouille-Viau, Dominick
    Pivneva, Irina
    Rossi, Carmine
    Guerin, Annie
    Kota, Vamsi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
12345